New treatment for pulmonary arterial hypertension

Adcirca (tadalafil) is a new treatment for pulmonary arterial hypertension (PAH) in adults.

Tadalafil is a potent and selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the breakdown of cyclic guanosine monophosphate (cGMP). It is already available as Cialis for the treatment of erectile dysfunction.

In patients with PAH, release of nitric oxide by the vascular endothelium is impaired, which results in reduced levels of cGMP in the pulmonary vascular smooth muscle. Tadalafil increases cGMP concentrations, leading to vasodilation of the pulmonary vascular bed.1


In a double-blind, pivotal study, investigators randomised 405 patients with PAH to receive placebo or tadalafil (2.5mg, 10mg, 20mg, or 40mg) orally once daily for 16 weeks. Approximately half the patients were already receiving background therapy with the endothelin receptor antagonist bosentan.

Tadalafil increased the distance walked in 6 minutes (the primary endpoint) in a dose-dependent manner; only the 40mg dose met the prespecified level of statistical significance (p<0.01). In the 79 patients receiving the 40mg dose who underwent postbaseline assessment, the mean placebo-corrected treatment effect was an improvement of 33 metres (95% CI 15–50 metres).2

View Adcirca drug record


  1. Adcirca Summary of Product Characteristics, November 2010.
  2. Galiè N et al. Circulation 2009; 119: 2894-903.

Further information: Lilly

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases